Editas Medicine (EDIT) Receivables (2015 - 2025)
Editas Medicine (EDIT) reported Receivables of $15.2 million for Q4 2025, down 6.7% year-over-year from $16.3 million in Q4 2024, and up 86.67% on a QoQ basis from $8.1 million in Q3 2025.
Editas Medicine (EDIT) has 11 years of Receivables data on file, last reported at $15.2 million in Q4 2025.
- Quarterly Receivables fell 6.7% year-over-year to $15.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15.2 million (down 6.7% YoY) and the FY2025 annual result came in at $15.2 million, down 6.7% from the prior year.
- Receivables advanced to $15.2 million in Q4 2025 per EDIT's latest filing, from $8.1 million in the prior quarter.
- Across five years, Receivables topped out at $16.3 million in Q4 2024 and bottomed at $120000.0 in Q3 2022.
- The 5-year median for Receivables is $630000.0 (2021), against an average of $3.3 million.
- The widest annual swing landed in 2021, when Receivables tumbled 95.59%; it then soared 6352.38% in 2025.
- Tracing EDIT's Receivables over 5 years: stood at $267000.0 in 2021, then jumped by 1826.97% to $5.1 million in 2022, then surged by 98.0% to $10.2 million in 2023, then soared by 59.67% to $16.3 million in 2024, then slipped by 6.7% to $15.2 million in 2025.
- Per Business Quant, the three latest EDIT Receivables figures stand at $15.2 million (Q4 2025), $8.1 million (Q3 2025), and $588000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 4.15 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 5.73 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - | 15.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15.18 Mn |
| Sep 30, 2025 | 8.13 Mn |
| Jun 30, 2025 | 588,000.00 |
| Mar 31, 2025 | 510,000.00 |
| Dec 31, 2024 | 16.27 Mn |
| Sep 30, 2024 | 126,000.00 |
| Jun 30, 2024 | 244,000.00 |
| Mar 31, 2024 | 245,000.00 |
| Dec 31, 2023 | 10.19 Mn |
| Sep 30, 2023 | 2.42 Mn |
| Jun 30, 2023 | 2.29 Mn |
| Mar 31, 2023 | 242,000.00 |
| Dec 31, 2022 | 5.15 Mn |
| Sep 30, 2022 | 120,000.00 |
| Jun 30, 2022 | 713,000.00 |
| Mar 31, 2022 | 1.37 Mn |
| Dec 31, 2021 | 267,000.00 |
| Sep 30, 2021 | 251,000.00 |
| Jun 30, 2021 | 331,000.00 |
| Mar 31, 2021 | 672,000.00 |
| Dec 31, 2020 | 6.05 Mn |
| Sep 30, 2020 | 1.06 Mn |
| Jun 30, 2020 | 1.87 Mn |
| Mar 31, 2020 | 1.83 Mn |
| Dec 31, 2019 | 418,000.00 |
| Sep 30, 2019 | 311,000.00 |
| Dec 31, 2018 | 30,000.00 |
| Sep 30, 2018 | 43,000.00 |
| Jun 30, 2018 | 362,000.00 |
| Mar 31, 2018 | 931,000.00 |
| Dec 31, 2017 | 679,000.00 |
| Sep 30, 2017 | 695,000.00 |
| Jun 30, 2017 | 820,000.00 |
| Mar 31, 2017 | 945,000.00 |
| Dec 31, 2016 | 88,000.00 |
| Sep 30, 2016 | 1.12 Mn |
| Jun 30, 2016 | 1.20 Mn |
| Mar 31, 2016 | 1.11 Mn |
| Dec 31, 2015 | 1.02 Mn |